Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

Next Previous
Trial Profile

Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Degarelix (Primary) ; Enzalutamide (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use

Most Recent Events

  • 30 Apr 2025 Results assessing acute effects of AR inhibition in hormone-sensitive mPC to identify therapeutic targets to prevent resistance, presented at the 116th Annual Meeting of the American Association for Cancer Research.
  • 06 Oct 2020 Results evaluating prostate multiparametric MRI (mpMRI) before and after neoadjuvant enzalutamide plus ADT, published in the Clinical Cancer Research
  • 24 Jun 2020 Results assessing morphologic effects of treatment with neoadjuvant enzalutamide and androgen deprivation therapy in high risk prostatic cancer, presented at the 111th Annual Meeting of the American Association for Cancer Research - II

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top